We search for ischemic stroke treatment knowing we have failed—intensely and often—to
translate mechanistic knowledge into treatments that alleviate our patients' functional …

Recent advances in stroke reperfusion therapies have led to remarkable improvement in
clinical outcomes, but many patients remain severely disabled, due in part to the lack of …

Background Neuroprotection for ischemic stroke is a growing field, built upon the elucidation
of the biochemical pathways of ischemia first studied in the 1970s. Beginning in the early …

Neuroprotection remains one of the holy grails of acute ischemic stroke therapy. The ability
to protect the ischemic brain from injury until reperfusion and then to protect the brain from …

Acute ischemic stroke (AIS) is a leading cause of disability and death worldwide. To date,
intravenous tissue plasminogen activator and mechanical thrombectomy have been …

Despite years of basic research and pioneering clinical work, ischemic stroke remains a
major public health concern. Prior STAIR (Stroke Treatment Academic Industry Roundtable) …

Neuroprotective therapies for acute ischaemic stroke have yet to be realised despite the
determined efforts of basic science and clinical investigators. Progressive elucidation of the …

Stroke is the leading cause of disability and thesecond leading cause of death worldwide.
With the global population aged 65 and over growing faster than all other age groups, the …

Background and Purpose—The concept of neuroprotection is based on sound scientific data
derived in preclinical studies. However, candidate neuroprotectants have never been …

Ischemic stroke remains a leading cause of morbidity and death for which few therapeutic
options are available. The development of neuroprotective agents, a once promising field of …